[New item for potential “at risk” launch of 40mg Glatopa in Feb 2017.]
Glatopa (20mg & 40mg) programs
• 2H16: FDA GDUFA date for NVS/MNTA’s 40mg-Copaxone ANDA.
• Aug 2016: USPTO decision on inter partes review regarding three of Teva’s Orange Book patents on 40mg Copaxone. (The IPR itself occurs on 5/12/16.)
• 26-Sep-2016: US District Court trial on all four of Teva’s Orange Book patents on 40mg Copaxone.
• Feb 2017: Potential NVS/MNTA “at risk” launch of 40mg Glatopa (assuming FDA approval has been obtained)—see #msg-122479122.
FoB program
• Mid 2016: Start phase-1 trial for Orencia FoB.
• Sep 2016: Oral arguments in USPTO inter partes review on BMY’s US Orencia patent.
• Late 2016/early 2017: Report phase-3 data for Humira FoB in psoriasis. 351(k) submission to FDA in 2017 with projected US launch in 2018 (subject to patent litigation—see #msg-118781959).
• 2016: MNTA expects to earn $60M in milestone payments from MYL (out of the $200M total) for meeting undisclosed FoB milestones.
• Jan 2017: USPTO decision on Orencia IPR.
• Timing unknown: Disclosures re five FoB compounds other than Orencia in MYL-MNTA partnership.
Lovenox program
• 2016: US District Court trial of NVS/MNTA vs AMPH/AGN on infringement of MNTA’s Lovenox patents, which could result in substantial damages payable to NVS/MNTA. (The Appellate Court remanded the case to the District Court on 11/10/15, finding that AMPH/AGN are not protected by the Hatch-Waxman Safe Harbor: #msg-118404904, #msg-115468100.)
• Mid 2016: Start phase-1 trials for first two of three sialylated-IVIG candidates (of which two are recombinant and one is plasma-derived). The third candidate will start phase-1 in 2017.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.